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Formation of the vascular system requires differentiation and
patterning of endothelial and smooth muscle cells (SMCs). Al-
though much attention has focused on development of the vas-
cular endothelial network, the mechanisms that control vascular
SMC development are largely unknown. Myocardin is a smooth
and cardiac muscle-specific transcriptional coactivator of serum
response factor, a ubiquitous transcription factor implicated in
smooth muscle gene expression. When expressed ectopically in
nonmuscle cells, myocardin can induce smooth muscle differenti-
ation by its association with serum response factor. Here we report
that mouse embryos homozygous for a myocardin loss-of-function
mutation die by embryonic day 10.5 and show no evidence of
vascular SMC differentiation. Myocardin is the only transcription
factor known to be necessary and sufficient for vascular SMC
differentiation.
The cardiovascular system is the first organ system to form andfunction during embryogenesis. Vascular development be-
gins with the organization of endothelial cells into a primitive
vascular plexus that becomes progressively remodeled to ulti-
mately form a complex vascular network (1). Smooth muscle
cells (SMCs) are recruited to the endothelial vasculature and
ensheathe it, providing support and contractility to the vascular
system. Several peptide growth factors and their tyrosine kinase
receptors have been shown to play key roles in assembly and
patterning of the endothelial vasculature and recruitment of
SMCs. In contrast, little is known of the transcriptional events
responsible for development of vascular SMCs in vivo.
Vascular SMCs are derived from a variety of embryonic
progenitors, including lateral mesoderm, cranial mesenchyme,
and the neural crest (2, 3). Differentiation of SMCs is triggered
by extracellular cues and is accompanied by the transcriptional
activation of an array of smooth muscle (SM) genes whose
products confer the unique contractile, morphological, and
structural properties that distinguish them from other muscle
cell types. The mcm1, Agamous, Deficiens, serum response
factor (SRF) box transcription factor plays a critical role in SM
gene activation. SRF binds to a DNA sequence known as a CArG
box, which is required for the expression of virtually every SM
gene analyzed to date (4–10). The importance of SRF for SM
gene expression has also been suggested by the finding that a
dominant-negative SRF mutant can block SM differentiation in
epicardial explant cultures (11). However, the role of SRF in SM
development in vivo has been clouded by the fact that SRF
knockout mice die during gastrulation from a lack of mesoderm
well before vascular development is initiated (12). Moreover,
because SRF is expressed throughout the embryo, it alone
cannot account for the specificity of SM gene transcription.
Thus, it has been proposed that SRF controls SM genes by
recruiting cell type-specific cofactors. Indeed, the transcriptional
activity of SRF in cultured cells can be modulated by its
association with positive and negative cofactors and by extra-
cellular signaling, but there is little or no direct evidence for the
involvement of either of these types of mechanisms in the control
of SM genes by SRF in vivo (13).
The SAP domain transcriptional coactivator, myocardin, is an
extraordinarily powerful SRF cofactor expressed specifically in
smooth and cardiac muscle cells (14). Myocardin selectively
activates smooth and cardiac muscle promoters by its interaction
with SRF. Expression of a dominant-negative myocardin mutant
in Xenopus embryos blocks heart formation, suggesting that
myocardin cooperates with SRF to activate cardiac gene expres-
sion (14). Interestingly, when expressed in nonmuscle cells in
vitro, myocardin activates smooth but not cardiac muscle gene
expression (15–18). Two myocardin-related transcription factors
(MRTFs) also associate with SRF but are expressed in more
widespread patterns during embryogenesis than myocardin (19).
To determine the function of myocardin during embryogen-
esis, we targeted the mouse myocardin gene by homologous
recombination. Here we show that mice lacking myocardin die
by embryonic day (E) 10.5 from a complete absence of vascular
SMCs. In contrast, cardiac development occurs normally in
myocardin mutant embryos. The avascular phenotype of myo-
cardin mutant mice, combined with previous studies demon-
strating that myocardin can activate expression of SM genes in
nonmuscle cells (15–18), demonstrates that myocardin is a
master regulator of SM development both sufficient and neces-
sary for SMC differentiation.
Methods
Generation of Myocardin Mutant Mice. The gene structure of
myocardin has been described (19). A myocardin-targeting vector
was constructed to delete exons 8 and 9 by using a pN-Z-TK2
vector, which contains a nuclear LacZ (nLacZ) cassette and a
neomycin-resistance gene under the control of the RNA poly-
merase II promoter and two herpes simplex virus thymidine
kinase (TK) gene cassettes (a generous gift of R. Palmiter,
University of Washington, Seattle). Genomic DNA flanking
myocardin exons 8 and 9 was PCR amplified from a mouse
129SvEv genomic DNA library (Stratagene) and inserted into
the targeting vector as short and long arms, respectively. The
targeting vector was electroporated into 129 SvEv-derived ES
cells, and selection was performed with G-418 and FIAU,
respectively. Four hundred ES cell clones were isolated and
analyzed by Southern blotting for homologous recombination.
Three clones with a disrupted myocardin gene were injected into
3.5-day mouse C57BL6 blastocysts, and the resulting chimeric
male mice were bred to C57BL6 females to achieve germline
transmission of the mutant allele.
RT-PCR. Total RNA was purified from tissues with TRIzol
reagent (Invitrogen) according to the manufacturer’s instruc-
tions. For RT-PCR, total RNA was used as a template for
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reverse transcriptase and random hexamer primers. Primer
sequences are available on request.
Immunostaining and Histology. Whole-mount staining for platelet-
endothelial cell adhesion molecule (PECAM) and SM -actin
was performed by using anti-mouse PECAM mAb MEC13.3
(Pharmigen) and SM -actin Ab (clone 1A4, Sigma), as de-
scribed (20). Embryos for histology were fixed in 4% parafor-
maldehyde, sectioned, and processed for in situ hybridization by
using standard procedures (21).
SM22-lacZ Transgenic Mice. Staining of transgenic embryos for
lacZ expression was performed as described (22). The SM22-
lacZ transgene contained the 1,343-bp SM22 promoter linked
to lacZ (22). The transgene was introduced into the myocardin
mutant background by interbreeding the appropriate strains
of mice.
Results
Generation of Myocardin Knockout Mice. To determine the function
of myocardin during mouse development, we generated myo-
cardin-deficient mice by targeted disruption of the myocardin
gene. The protein-coding region of the mouse myocardin gene
encompasses 13 exons and spans 93 kb of genomic DNA (Fig.
1A). Exons 8 and 9, which encode the basic domain, glutamine-
rich domain, and part of the SAP domain (19), were replaced
with a promoterless lacZ gene and a neomycin-resistance gene
(Fig. 1 A). The basic and glutamine-rich domains are required for
interaction with SRF. Deletion of these domains abolishes all
myogenic activity of myocardin (14, 18). Thus, this mutation
inactivates the gene.
The targeting vector was electroporated into 129SVEv ES
cells and targeted clones were identified by Southern blot
analysis of genomic DNA (Fig. 1B). ES cells heterozygous for the
targeted myocardin gene were injected into C57BL6 blastocysts
to generate chimeric mice, which transmitted the mutant allele
through the germ line.
Mice heterozygous for the mutant myocardin allele were
viable, fertile, and phenotypically normal. Genotyping of off-
spring from heterozygous intercrosses in the isogenic 129 back-
ground or in a 129C57BL6 mixed genetic background yielded
WT and myocardin/ mice in an approximate 1:2 ratio but no
myocardin/ mice, indicating that the homozygous mutation
resulted in embryonic lethality. Analysis of the genotypes of
embryos from timed matings showed Mendelian ratios up to
E10.5 but no live homozygous mutants at later developmental
time points.
To confirm the gene-targeting event, we performed RT-PCR
analysis of mRNA from the hearts of WT and mutant embryos
at E9.5, using primers representing exon sequences within and
surrounding the deleted region of the gene (Fig. 1C). These
assays revealed that exons 8 and 9 of myocardin were replaced
with the LacZ-Neo cassette, as expected, and that this mutation
resulted in alternative splicing of the targeted allele, such that
exon 7 was spliced to exon 10. This was further confirmed by
sequence analysis of RT-PCR products. Because of such alter-
native splicing, the lacZ gene was not expressed in mutant mice
(data not shown). Notably, the truncated transcript generated
from the mutant allele was expressed at a much lower level than
the WT myocardin transcript, presumably because of instability
of the mutant transcript (Fig. 1C).
Because myocardin shares extensive amino acid homology
with MRTF-A and MRTF-B, which can also act as SRF cofactors
(19), we assayed their expression by RT-PCR of RNA from
hearts of E9.5 embryos. As shown in Fig. 1D, both transcripts
Fig. 1. Generation of myocardin mutant mice. (A) Targeting strategy. Homologous recombination resulted in deletion of exons 8 and 9 and insertion
of lacZ and neomyocin-resistance cassettes. The positions of 5 and 3 probes used for Southern analysis in B are shown. Intron junctions within the coding
region are shown by arrowheads beneath the schematized protein. Exons are shown in boxes, and sizes of introns are indicated. (B) Southern blot analysis.
Genomic DNA from ES cell clones was isolated from tail biopsies and analyzed by Southern blot with 5 and 3 probes after digestion with EcoRI. The
positions of WT and mutant bands are shown. (C) Analysis of myocardin transcripts by RT-PCR. RNA was isolated from hearts of WT and myocardin mutant
embryos at E9.5 and analyzed by RT-PCR by using different pairs of primers, as shown to the left of each panel. Genotypes are shown at the top. A schematic
of exons (E) with positions of primers is shown at the right. Transcripts for GAPDH were detected as a control for RNA loading and integrity. In the targeted
allele, exon 7 is spliced to exon 10. (D) RNA was isolated from hearts of WT and myocardin mutant embryos at E9.5 and analyzed for myocardin, MRTF-A,
and MRTF-B transcripts by RT-PCR.














were readily detectable in WT and mutant hearts, and neither
was up-regulated in the absence of myocardin.
Lethal Vascular Abnormalities in Myocardin Mutant Embryos. Anal-
ysis of myocardin/ embryos obtained from timed matings
revealed no abnormalities before E8.0, and most embryos ap-
peared to develop normally up to E8.5 (data not shown).
However, homozygous mutant embryos could be readily iden-
tified at E9.5 by their pale yolk sacs, which lacked blood vessels
(Fig. 2A a–d). Homozygous mutant embryos also showed growth
retardation and delayed development at E9.5. The gross mor-
phology of the hearts in mutant embryos appeared normal with
completed rightward looping and normal chamber formation.
Histological analysis of transverse sections of mutant embryos
at E9.5 confirmed the normal appearance of the atrial and
ventricular chambers but revealed severe vascular defects in
which the dorsal aortae were clearly underdeveloped (Fig. 2B).
However, the anterior cardinal veins appeared normal in mutant
embryos at this stage. It is noteworthy that SM marker genes are
not yet activated in the cardinal veins of WT embryos, whereas
differentiated SMCs are present in the dorsal aortae at this stage.
By E10.5, mutant embryos were severely delayed developmen-
tally and pericardial effusion was often observed, indicative of
cardiovascular insufficiency (Fig. 2 A e and f ).
Normal Endothelial Cell Differentiation and Organization in Myocar-
din/ Embryos. Vascular development initiates around E7.5 in
the mouse with the differentiation and migration of endothelial
progenitor cells (1–3). To visualize the embryonic vasculature,
we performed whole-mount Ab staining for PECAM-1, an
endothelial marker (23). At E8.5, PECAM staining of the newly
formed vasculature was indistinguishable in WT and myocardin
mutant embryos (data not shown). At E9.5, differentiated
endothelial cells were properly positioned in mutant embryos,
even though mutant embryos began to show growth retardation
by this stage (Fig. 3 A and B). Notably, the complexity and
patterning of the cranial vasculature, the intersomitic vascula-
ture, and the dorsal aorta as revealed by PECAM-1 staining
appeared similar in WT and myocardin mutant embryos. Trans-
verse sections clearly showed the presence of PECAM-1-positive
endothelial cells in the dorsal aorta and cardinal veins of both
WT and mutant embryos, although the dorsal aorta in mutant
embryos was smaller than normal (Fig. 3 C–F). Similarly,
PECAM staining was detected in the endocardial layer of the
heart of WT and myocardin mutant embryos. These findings
indicated that vascular endothelial cell differentiation and or-
ganization were unaffected by the myocardin mutation.
Defects in Vascular SMC Differentiation in Myocardin/ Embryos. To
determine whether the vascular abnormalities in myocardin
mutant embryos resulted from a defect in SMC differentiation,
we stained E9.5 embryos with an Ab to SM -actin. As shown
in Fig. 4A, SM -actin-positive SMCs were present in the dorsal
aorta and cardinal veins of WT embryos. However, no such SM
-actin-positive cells were detected in the vasculature of myo-
cardin/ embryos. Comparison of transverse sections of SM
-actin-stained embryos revealed that SMCs were missing from
the dorsal aortae of myocardin/ embryos (Fig. 4A). Unex-
pectedly, however, there was no decrease in the expression of SM
-actin in myocardin/ hearts.
We further examined the expression of SM genes by in situ
hybridization to embryo sections at E9.5 (Fig. 4B). The SM22
and SM -actin genes are direct target genes of SRF and are
induced by myocardin in transfected fibroblasts (5–7, 14, 18).
Transcripts for both genes were expressed in the heart and
developing vasculature of WT embryos (Fig. 4B). In contrast,
neither transcript was detected in the vasculature of myocar-
din/ embryos, although normal expression was detected in the
hearts of mutant embryos. The atrial natriuretic factor (ANF)
gene, a cardiac-specific target of myocardin, was also expressed
normally in mutant embryos. These findings demonstrated that
vascular SMC differentiation was specifically disrupted in myo-
cardin/ embryos, which is the likely cause of vascular abnor-
malities and embryonic lethality.
Fig. 2. (A) Vascular abnormalities
in myocardin mutant embryos.
Shown are WT and mutant yolk sacs
and embryos at E9.5 and E10.5. In e
and f, the yolk sacs were removed
from the embryos shown in c and d.
(B) Hematoxylineosin sections of
WT and mutant embryos at E9.5.
(Lower) High magnifications of the
region with the dorsal aorta, indi-
cated by an arrowhead.
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Expression of SM22-lacZ in Myocardin/ Embryos. The SM22 pro-
moter contains two CArG boxes that are required for expression in
smooth, cardiac, and skeletal muscle cells at E9.5 and for transac-
tivation of the promoter by myocardin in vitro (4, 5, 14). The finding
that the endogenous SM22 gene was expressed in the heart of
myocardin/ embryos raised the question whether this promoter
region was regulated by myocardinSRF in vivo or whether another
regulatory region was able to sustain the expression of SM22 in the
heart of mutant embryos. We therefore introduced an SM22-lacZ
transgene into the myocardin mutant background by breeding to
the corresponding transgenic line. As shown in Fig. 5, SM22-lacZ
expression was specifically ablated in the dorsal aortae of
Fig. 3. Endothelial cell patterning detected by PECAM staining is unperturbed in myocardin mutant embryos. (A and B) WT and myocardin mutant embryos
at E9.5 stained for PECAM. The arrowhead points to the dorsal aorta. (C–F) Histological sections of embryos stained for PECAM (C and E, WT; D and F,
myocardin/). E and F show high magnifications of the region of the dorsal aorta, indicated by arrowheads. cv, cardinal vein; da, dorsal aorta; h, heart; nt, neural
tube.
Fig. 4. Lack of expression of SM markers in myocardin mutant embryos. (A) WT and myocardin mutant embryos at E9.5 stained for SM -actin. The arrowhead
points to the dorsal aorta. (B) Detection of smooth and cardiac muscle transcripts by in situ hybridization to E9.5 embryo sections. Silver grains are shown
pseudocolored red. Arrowheads point to the dorsal aortae.














homozygous mutant embryos, but not in the heart or somites,
confirming that myocardin is required specifically for vascular
SM gene expression.
Discussion
The phenotype of myocardin mutant mice reveals an essential
role of myocardin in differentiation of vascular SMCs. These
findings coupled with previous studies demonstrating the ability
of myocardin to induce SM gene expression in nonmuscle cells
(15–18) establish myocardin as the only transcription factor
known to be both necessary and sufficient for SM differentiation.
The Role of Myocardin in SM Development. SRF has been reported
to activate SM genes in transfection assays by recruiting several
other cofactors. For example, the homeodomain protein Mhox
and two AT-rich DNA-binding proteins referred to as
MRF and  have been proposed as SM-restricted activators of
SRF target genes (24, 25). The combination of GATA6 and LIM
domain proteins of the cysteine-rich lim-only protein family has
also been reported to be sufficient and necessary for SM gene
expression in transfected cells, apparently by enhancing SRF
DNA binding (26). However, it remains unclear which, if any, of
these purported SRF cofactors are essential for SM gene ex-
pression in vivo or whether there is so much redundancy among
SRF cofactors that no single cofactor is indispensable for SM
gene activation.
The abnormalities in vascular development in myocardin mutant
embryos are highly specific to SMCs and occur in the absence of
associated cardiac abnormalities, which contrasts with numerous
other mouse mutants in which vascular demise is secondary to
cardiac dysfunction. The complete block of SM development in
myocardin/ embryos demonstrates that myocardin is an essential
activator of the SM differentiation program in vivo and that no
other factor can substitute for this promyogenic function, despite
numerous reports that other transcription factors can cooperate
with SRF to stimulate SM gene expression in vitro. These findings
also demonstrate that SRF alone is incapable of activating SM
target genes in vivo without recruiting myocardin.
Myocardin and Cardiac Gene Expression. Based on the absence of
cardiac gene expression in Xenopus embryos expressing a
dominant-negative myocardin mutant, and the ability of myo-
cardin to activate cardiac gene promoters in transfection assays
(14), we anticipated that myocardin would be required for heart
development in the mouse. Nevertheless, we detected no abnor-
malities in cardiac morphogenesis or gene expression in myo-
cardin mutant embryos. Even direct target genes of myocardin,
such as SM22, SM -actin, and ANF were expressed normally in
the heart.
How can these findings be explained? We favor the possi-
bility that MRTF-A or -B, which are expressed in the devel-
oping heart (19), or other cardiac transcription factors, may
substitute for myocardin at this early stage, and such redun-
dancy is lacking in the SM lineage. It is interesting to note that
the early heart tube resembles a vessel and expresses many
SM genes, which are later down-regulated. We propose that
myocardin controls an early muscle regulatory program shared
by the smooth and cardiac muscle lineages and that cardiac
muscle cells possess additional myogenic regulators that mod-
ify this program. Combining the myocardin mutation with
mutations in MRTF genes or other cardiac transcription
factors should further illuminate the potential role of myocar-
din in the developing heart.
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Fig. 5. Ablation of SM expression of SM22-lacZ in myocardin mutant em-
bryos. (A and B) WT and myocardin/ mutant embryos harboring an SM22-
lacZ transgene were stained for lacZ expression at E9.5. Arrowheads point to
the dorsal aortae. (C–F) Sections of WT and mutant embryos from A and B
counterstained with light eosin (C and E, WT; D and F, myocardin/). E and F
show low magnifications to include the heart. Arrowheads point to the dorsal
aortae.
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